Vernalis Notes the Acquisition of RedoxTherapies by Juno Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Leerink Affirms Juno Therapeutics (JUNO) at 'Outperform'; Latest Deal Adds A2a Antagonist to CAR-T Pipeline
July 15, 2016 6:24 AM EDTLeerink affirms Juno Therapeutics (Nasdaq: JUNO) with an Outperform rating and $86 price target following news that the company moved to acquire RedoxTherapies
On the deal, analyst Michael Schmidt commented, JUNO plans to evaluate vipadenant in combination with CAR-T cell products, potentially... More
